SCHEMBL24176348

SCHEMBL24176348

NC(=O)c1cnc(-c2ncccn2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
GSK3B P49841 2/20 0.44
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
MAPT P10636 3/20 0.44
NFKB1 P19838 1/20 0.39
PPARG P37231 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
NCOA2 Q15596 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
CYP1A2 P05177 1/20 0.39
HDAC1 Q13547 2/20 0.38
HDAC6 Q9UBN7 1/20 0.38
ADORA3 P0DMS8 1/20 0.37
TSHR P16473 1/20 0.37
MC4R P32245 1/20 0.37
ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5008045 0.85 HCAR2 (0.52) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL9980510 0.80 GSK3B (0.44) ALDH1A1GSK3BNPC1RAB9ASMN1; SMN2
SCHEMBL6609203 0.80 ALDH1A1 (0.72) ALDH1A1GSK3BNPC1RAB9ASMN1; SMN2
SCHEMBL30664409 0.80 ALDH1A1 (0.72) ALDH1A1GSK3BNPC1RAB9ASMN1; SMN2
SCHEMBL12571419 0.79 ALDH1A1 (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL21563726 0.77 PTPN1 (0.43) ALDH1A1GSK3BNPC1RAB9ASMN1; SMN2
SCHEMBL23080977 0.77 ALDH1A1 (0.45) ALDH1A1GSK3BNPC1RAB9ASMN1; SMN2
SCHEMBL892779 0.76 MAPT (0.68) ALDH1A1GSK3BNPC1RAB9ASMN1; SMN2
SCHEMBL10848656 0.75 CDC7 (0.61) ALDH1A1GSK3BNPC1RAB9ASMN1; SMN2
SCHEMBL5392323 0.75 CYP3A4 (0.56) ALDH1A1GSK3BNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220002796-A1 QUALITY CONTROL OF LNA OLIGONUCLEOTIDE THERAPEUTICS USING MASSIVELY PARALLEL SEQUENCING ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2022-01-06 US disclosed